Ablynx gains on Phase II RA data

Ablynx N.V. (Euronext:ABLX) gained EUR 0.94 (18%) to EUR 5.78 on Thursday after reporting interim Phase II data of IV ALX-0061 to treat moderate to severe active rheumatoid arthritis (RA). In 34 evaluable patients on a stable background of methotrexate, 3 mg/kg doses of anti-IL-6R every four weeks significantly improved ACR20 response rate at week 12 vs. placebo (80% vs. 17%, p<0.05). ALX-0061 also improved ACR20 response rates at week 12 vs. placebo when given in doses of 1 mg/kg every four weeks (67%) and 6 mg/kg every 8 weeks (56%), but the results were not significant. ...